Last reviewed 2026-04-20 · How we verify

Adjuvant PD-1 inhibitors

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Vomiting
• Nausea
• Fatigue
• Pyrexia
• Abdominal pain
• Headache
• RCCEP
• Abdominal distension
• Chills
• Injection site reaction
• Pain
• Arthralgia

Key clinical trials

• Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
• A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection (PHASE1, PHASE2)
• GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study (PHASE1)
• Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
• Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma (PHASE3)
• A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy (PHASE2)
• Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
• A Single-arm, Phase II, Multi-center Clinical Trial of Sintilimab During the Perioperative Period in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Adjuvant PD-1 inhibitors CI brief — competitive landscape report
• Adjuvant PD-1 inhibitors updates RSS · CI watch RSS
• Tongji Hospital portfolio CI